Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects

التفاصيل البيبلوغرافية
العنوان: Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects
المؤلفون: Lian-Di Kan, Liu-Cheng Li
المصدر: Journal of Ethnopharmacology
سنة النشر: 2016
مصطلحات موضوعية: PQ, paraquat, Active ingredient, NQO1, NAD(P)H:quinone oxidoreductase 1, GC-MS, gas chromatograph-mass spectrometer, HSYA, hydroxy safflor yellow A, Traditional Chinese medicine, TNF-α, tumor necrosis factor-α, ESA, eclipta saponin A, Triptolide (PubChem CID: 107985), BA, boswellic acids, 0302 clinical medicine, LPO, lipid peroxide, HLF, human lung fibroblasts, Drug Discovery, Pulmonary fibrosis, CCl4, carbon tetrachloride, GSH, glutathione, Medicine, GR, glutathione reductase, Glycosides, ET, endothelin, PARP, poly ADP-ribose polymerase, HO-1, heme oxygenase-1, EGCG, epigallocatechin-3-gallate, FB, fibroblasts, LPA1, lysophosphatidic acid receptor 1, LDH, lactate dehydrogenase, Drug discovery, Tanshinone IIA (PubChem CID: 164676), Celastrol (PubChem CID: 122724), PMVEC, pulmonary microvascular endothelial cells, MCP-1, monocyte chemoattractant protein-1, Andro, Andrographolide, Res, resveratrol, ECM, extracellular matrix, 030220 oncology & carcinogenesis, EndoMT, endothelial-mesenchymal transition, iNOS, inducible nitric oxide synthase, p-Smads, phosphorylated Smads, AMs, alveolar macrophages, Mechanism, TIMP, tissue inhibitor of metalloproteinase, HMGB1, high-mobility group box 1, medicine.medical_specialty, SAA, salvianolic acid A, DSQRL, Decoction for Strengthening Qi and Replenishing Lung, PF, pulmonary fibrosis, CP, cyclophosphamide, Quercetin (PubChem CID: 5280343), HSM, Hirsutella sinensis mycelium, Article, 03 medical and health sciences, Humans, miR, miRNA, MFb, myofibroblasts, SARS, severe acute respiratory syndrome, Tan IIA, tanshinone IIA, Intensive care medicine, ARDS, acute respiratory distress syndrome, FN, fibronectin, NS, Nigella sativa L, Pharmacology, MDA, malondialdehyde, HELFs, human embryonic lung fibroblast, SOD, superoxide dismutases, GBA, gambogic acid, Medical practice, medicine.disease, SP-D, surfactant protein-D, ANG, angiotensin, IL, interleukin, Clinical trial, RPF, rapid pulmonary fibrosis, 030104 developmental biology, Eclipta saponin A (PubChem CID: 476537), DBTG, total glucosides of Danggui-Buxue-Tang, TAL, triterpene acids of loquat, CAT, catalase, Paeoniflorin (PubChem CID: 442534), 0301 basic medicine, ALI, acute lung injury, LC3A/B, light chains 3A/B, NLRP, NOD-like receptor, Pulmonary Fibrosis, Hyp, hydroxyproline, MPO, myeloperoxidase, PDGF, platelet-derived growth factor, T-AOC, total antioxidant capacity, ACE, angiotensin converting enzyme, BALF, bronchoalveolar lavage fluid, Keap, Kelch like ECH-associated protein, Medicine, Chinese Traditional, NF-κB, nuclear factor kappa B, BLM, bleomycin, SY, safflor yellow, NOX, NADPH oxidase, VEGF, vascular endothelial growth factor, MMP, matrix metalloproteinase, Curcumin (PubChem CID: 969516), LOX, lipooxygenase, Nrf2, nuclear factor erythroid 2-related factor, TGF-β1, transforming growth factor-β1, Flavanones, LPS, lipopolysaccharide, Quercetin, TCM, traditional Chinese medicine, EMT, epithelial-mesenchymal transition, AEC, alveolar epithelial cells, Col-I, collagen types I, OM, Oxymatrine, mKG, Modified Kushen Gancao Formula, RPFS, Renshen pingfei decoction, BECs, bronchial epithelial cells, CTGF, connective tissue growth factor, α-SMA, α-smooth muscle actin, Lung Disorder, GCA, glycyrrhizic acid, OVA, ovalbumin, ROS, reactive oxygen species, Phenols, BAI, Baicalein, Animals, IFN, interferon, PG, prostaglandin, YPF-G, total glycoside of Yupingfeng, THP, tetrahydropalmatine, TPL, triptolide, Herb, business.industry, Mechanism (biology), Terpenes, FEV1, forced expiratory volume in one second, Paclitaxel (PubChem CID: 36314), HC, Houttuynia cordata, GA, gallic acid, EOCR, essential oil of Citrus reticulata, GPx, glutathione peroxidases, TQABDA, Tonifying Qi, Activating Blood and Dispersing Accumulation, IR, irradiation, Baicalein (PubChem CID: 5281605), Processing methods, FGF, fibroblast growth factor, COX, cyclooxygenase, PTX, paclitaxel, Tectorigenin (PubChem CID: 5281811), α-terpineol (PubChem CID: 17100), MAPK, mitogen-activated protein kinases, XRT, x-ray treatment, FVC, forced vital capacity, VASH, Vasohibin, COL1A1, procollagen type 1 a1, business, Phytotherapy, HPMECs, human pulmonary microvascular endothelial cells
الوصف: Ethnopharmacological relevance Pulmonary fibrosis (PF) is a chronic, debilitating and often lethal lung disorder. Despite the molecular mechanisms of PF are gradually clear with numerous researchers’ efforts, few effective drugs have been developed to reverse human PF or even halt the chronic progression to respiratory failure. Traditional Chinese medicine (TCM), the main component of the medical practice used for more than 5000 years especially in China, often exerts wider action spectrum than previously attempted options in treating human diseases. Recent data have shown the anti-fibrotic benefits of the active ingredients from TCM in this field, which may represent an attractive source of the drug discovery against PF. Aim of the review This review summarizes the pre-clinical and clinical evidence on the benefits of TCM and their active ingredients, and provides a comprehensive information and reliable basis for the exploration of new treatment strategies of botanical drugs in the therapy of PF. Methods The literature information was obtained from the scientific databases on ethnobotany and ethno medicines (up to Aug 2016), mainly from the Pubmed, Web of Science and CNKI databases, and was to identify the experimental studies on the anti-fibrotic role of the active agents from TCM and the involved mechanisms. The search keywords for such work included: “lung fibrosis” or “pulmonary fibrosis”, and “traditional Chinese medicine”, “extract” or “herb”. Results A number of studies have shown that the active agents of single herbs and TCM formulas, particularly the flavonoids, glycosides and alkaloids, exhibit potential benefits against PF, the mechanisms of which appear to involve the regulation of inflammation, oxidant stress, and pro-fibrotic signaling pathways, etc. Besides, the processing methods for discovering TCM in treating PF were prospectively discussed. Conclusion These research work have shown the therapeutic benefits of TCM in the treatment of PF. However, more continued researches should be undertaken to clarify the unconfirmed chemical composition and regulatory mechanisms, conduct standard clinical trials, and evaluate the possible side effects. The insights provided in present review will be needed for further exploration of botanical drugs in the development of PF therapy.
Graphical abstract fx1
تدمد: 1872-7573
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83f97bf29106c253c558febd6a4a85a0
https://pubmed.ncbi.nlm.nih.gov/28038955
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....83f97bf29106c253c558febd6a4a85a0
قاعدة البيانات: OpenAIRE